| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_190a9c0e7ea3c3c2a426bc601c2d32bb |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N- |
| filingDate |
2004-12-07^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-07-31^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9c55247dad203bdfa56fabf6482b98a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d92a6191b3ea582bdeec54cc87b3451
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30584bde882603bbe78a9f66122ce02f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_52452589611da776600a3f03ea96b9de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a72b05edc7c295b8501a89b97c410919
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95adda882e06fcc997c0753e29d9087b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44ed873c95e8502ec0ea1c46e0045b1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0388c9fac92df10ffe794616430c182a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c41776f540c0801aa0aa74f675bcad3d |
| publicationDate |
2007-07-31^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7250258-B2 |
| titleOfInvention |
CDK5 genetic markers associated with galantamine response |
| abstract |
Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011084757-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008166723-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011085334-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010123625-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010123626-A1 |
| priorityDate |
2003-12-15^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |